With numerous studies in stage 3 trials, the opportunities to leverage psilocybin for clinical care is likely to expand in the next few years. Matt Stang shares his excitement for the future of this agent as means to help more patients.

To learn more on psilocybin and earn CME credit, see Psilocybin Revisited: The Science Behind the Drug and Its Surprising Therapeutic Potential.

Mr Stang is the founder of Delic Corp.